Chinese manufacturer specializing in targeted anticancer drug APIs and intermediates. Focuses on kinase inhibitor APIs (TINI class). Main products include Crizotinib, Afatinib, Capmatinib, Sorafenib, Ibrutinib, Lenvatinib, Acalabrutinib, Tucatinib, Upadacitinib, Deucravacitinib, Filgotinib, and Ritlecitinib. Has 500 sq meter pilot laboratory in Zhangjiang (Shanghai) with glass reactors (50L, 100L) and rotary evaporators, and an amplification plant in Jiaozhou, Qingdao for 100kg to tonnage scale. Had 1 FDA inspection with OAI outcome (2010). Note: listed headquarters as China but no clear website domain registration.
Targeted anticancer API synthesis, kinase inhibitor manufacturing (Crizotinib, Afatinib, Ibrutinib, Lenvatinib, Sorafenib), JAK inhibitor APIs (Upadacitinib, Ritlecitinib), custom synthesis scale-up from 10kg pilot to tonnage.
1 site worldwide
No certifications on file yet.
No reviews available yet.
No documents available.